Cumate-Inducible AAV Cap And Rep Expression for Cell Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Constitutive expression of rep genes in AAV packaging cell lines is undesirable due to cytostatic and cytotoxic effects, leading to reduced cell growth and stability, and existing inducible systems are not effectively applied to AAV gene regulation.
Innovation Solution
A dual-control system using cumate operator (CuO) sequences and a cumate repressor protein (CymR) to regulate AAV cap and rep gene expression, allowing for inducible control of AAV gene transcription, including adenoviral proteins, through a minimal promoter and CymR-transcriptional activator domain polypeptide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If rep genes are constitutively expressed in AAV packaging cell lines, then AAV production capability is improved, but cell growth and stability deteriorate due to cytostatic and cytotoxic effects
Solution Approach 1:
The patent applies inducible promoter systems that allow dynamic control of rep gene expression. The promoter can be switched from an active state (enabling high-level rep gene expression for AAV production) to an inactive state (reducing expression to minimize cytotoxic effects). This dynamic regulation resolves the contradiction by allowing the system to adapt its expression level based on production needs versus cell health requirements.
2Object-affected harmful factors
If inducible promoter systems are used to control rep gene expression, then cell toxicity is reduced, but expression control precision deteriorates compared to constitutive expression
Solution Approach 1:
The patent employs promoter systems with adjustable parameters including induction strength, induction timing, and expression level modulation. By changing these parameters, the system achieves both reduced toxicity (through controlled induction) and precise expression control (through tunable induction levels). The inducible promoter responds to specific inducers with quantifiable expression changes, maintaining manufacturing precision while reducing harmful effects.
Data Source
AI summary
The invention relates to nucleic acid molecules, vectors and plasmids comprising AAV cap genes and rep genes, wherein the cap and rep genes are both operably-associated with an inducible promoter which comprises one or more cumate operator (CuO) sequences. The invention further relates to producer and packaging cell lines which are useful in the production of Adeno-Associated Virus (AAV) particles.